智通财经APP讯，兴齐眼药(300573.SZ)发布公告，近日，公司收到国家药品监督管理局签发的关于SQ-23082滴眼液的《药物临床试验批准通知书》。SQ-23082滴眼液为公司研发的化学药品2.1类改良型新药。临床拟用于过敏性结膜炎相关的眼痒的治疗。根据改良型新药的有关要求，公司已经完成SQ-23082滴眼液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-23082滴眼液具有良好的安全性及临床开发价值。目前国内外尚无该眼用制剂产品上市。
智通财经APP讯，兴齐眼药(300573.SZ)发布公告，近日，公司收到国家药品监督管理局签发的关于SQ-23082滴眼液的《药物临床试验批准通知书》。SQ-23082滴眼液为公司研发的化学药品2.1类改良型新药。临床拟用于过敏性结膜炎相关的眼痒的治疗。根据改良型新药的有关要求，公司已经完成SQ-23082滴眼液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-23082滴眼液具有良好的安全性及临床开发价值。目前国内外尚无该眼用制剂产品上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.